NasdaqCM - Nasdaq Real Time Price USD

Moleculin Biotech, Inc. (MBRX)

1.0300

-0.0200

(-1.90%)

At close: April 23 at 4:00:01 PM EDT

1.0400

+0.01

+(0.97%)

Pre-Market: 8:59:04 AM EDT

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that an abstract regarding the Company’s next-generation anthracycline, Annamycin, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, at the McCor

GlobeNewswire 7 days ago

MBRX
-1.90%
Moleculin Biotech doses first patient in Phase 3 MIRACLE trial

Moleculin Biotech (MBRX) announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine for the treatment of AML patients who are refractory to or relapsed after induction therapy. This Phase 3 “MIRACLE” trial is a global approval trial, including sites in the US, Europe and the Middle East. “The start of patient dosing represents a huge milestone for Moleculin and importantly, the AML community,” commented Walter Klemp, Chairman and C

TipRanks 22 days ago

MBRX
-1.90%
Moleculin Biotech begins dosing subjects in combination therapy trial for AML

The trial includes sites across Europe, the Middle East and the US.

Clinical Trials Arena 22 days ago

MBRX
-1.90%
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now

Moleculin Biotech (MBRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 22 days ago

MBRX
-1.90%
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine (also known as “Ara-C” and for which the combination of Annamycin and Ara-C

GlobeNewswire 23 days ago

MBRX
-1.90%
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy

Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 28 days ago

MBRX
-1.90%
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ...

Despite significant progress in clinical trials, Moleculin Biotech Inc (MBRX) faces financial hurdles with limited cash runway and high trial costs.

GuruFocus.com 30 days ago

MBRX
-1.90%
Q4 2024 Moleculin Biotech Inc Earnings Call

Q4 2024 Moleculin Biotech Inc Earnings Call

Thomson Reuters StreetEvents 30 days ago

MBRX
-1.90%
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

– Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in the first quarter of 2025 – Multiple subjects currently being screened in first MIRACLE site activated – Initial data readout of the Phase 3 MIRACLE trial expected in the second half of 2025 – Company to host conference call and webcast today, Monday, March 24th at 8:30 AM ET HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MB

GlobeNewswire last month

MBRX
-1.90%
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2024, on Friday afternoon, March 21, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Monda

GlobeNewswire last month

MBRX
-1.90%
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company") a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it participated in the Virtual Investor "Top 5 for '25" On-Demand Conference.

PR Newswire last month

MBRX
-1.90%
Moleculin to Present at the 37th Annual ROTH Conference

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Walter Klemp, Chairman and Chief Executive Officer of Moleculin will participate in a fireside chat on Tuesday, March 18, 2025 at 11:00 AM PT at the 37th Annual ROTH Conference being held in Dana Point, CA.

PR Newswire last month

MBRX
-1.90%
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received a Notice of Intent to Grant for the European patent application titled, "Method of Reconstituting Liposomal Annamycin". The grant is subject to payment of fees and completion of final amendments and formalities. Such grant will enhance the global exclusivity of Annamycin with t

PR Newswire last month

MBRX
-1.90%
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced its abstract has been accepted for poster presentation at the Acute Leukemias XIX (ISALXIX) International Symposium being held March 16-19, 2025 in Munich, Germany.

PR Newswire last month

MBRX
-1.90%
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 3,271,029 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering and warrants to purchase up to 6,542,058 shares of common stock in a con

PR Newswire last month

MBRX
-1.90%
Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

On Thursday, Moleculin Biotech, Inc., (NASDAQ:MBRX) stock is surging with a strong session volume of 64.85 million compared to an average volume of 157.048K, as per data from Benzinga Pro. The company received FDA feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 pivotal trial protocol evaluating Annamycin in combination with Cytarabine (also known as Ara-C and for which the combination of Annamycin and Ara-C is referred to as AnnAraC) for refract

Benzinga 2 months ago

MBRX
-1.90%
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 5,828,570 shares of common stock of the Company originally issued in December 2023 and August 2024 all at a reduced exer

PR Newswire 2 months ago

MBRX
-1.90%
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received U.S. Food and Drug Administration ("FDA") feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 pivotal trial protocol evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of An

PR Newswire 2 months ago

MBRX
-1.90%
Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine

The trial is set to include sites across Europe, the Middle East and the US.

Clinical Trials Arena 2 months ago

MBRX
-1.90%
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received first country regulatory approval in Europe to begin recruiting for its Phase 3 pivotal trial protocol evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as "AnnAraC") for the treatm

PR Newswire 2 months ago

MBRX
-1.90%

Performance Overview

Return	MBRX	S&P 500 (^GSPC)
YTD	-39.41%	-8.60%
1-Year	-77.61%	+6.02%
3-Year	-43.41%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Moleculin Biotech, Inc. (MBRX)

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial

Moleculin Biotech begins dosing subjects in combination therapy trial for AML

Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ...

Q4 2024 Moleculin Biotech Inc Earnings Call

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin to Present at the 37th Annual ROTH Conference

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Performance Overview